Home
About
About UniQure
Management
Board of Directors
Careers
Gene Therapy
Gene Therapy
Disease Areas
R&D
Pipeline
Platform
Programs
Collaborations
Scientific Publications
Scientific Meetings
Products
Glybera
Investors
Shareholder Information
Financial Reports
Event Calendar
Corporate Governance
STAK
News
Latest Press Releases
Media Kit
search
Latest News 2012
May 21, 2013
uniQure and consortium to receive EUR 2.5 million Eurostars grant to develop RNAi gene therapy for Huntington’s disease
May 14, 2013
uniQure raises EUR 14.1m in new investment led by Coller Capital
Feb 20, 2013
uniQure Named to MIT Technology Review’s 2013 50 Disruptive Companies List Recognizing World’s Most Innovative Companies
Jan 22, 2013
uniQure Appoints Philip Astley-Sparke President US
Dec 11, 2012
uniQure initiates Phase I in acute intermittent porphyria
Dec 6, 2012
uniQure Appoints Hans Christian Rohde Chief Commercial Officer
Dec 5, 2012
uniQure licenses RNA interference technology to advance Huntington’s disease program
Nov 5, 2012
uniQure Provides Business Update for the Third Quarter 2012
Nov 2, 2012
uniQure’s Glybera® First Gene Therapy Approved by European Commission
Sep 7, 2012
uniQure Reports Half Year Results 2012
Jul 20, 2012
First gene therapy in Western world receives positive opinion in Europe from CHMP
Jul 6, 2012
Notice to convene the Meeting of Holders of Depositary Receipts of Stichting Administratiekantoor uniQure B.V.
Jun 20, 2012
uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson’s Disease
Jun 18, 2012
uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy
Apr 26, 2012
Overview of key transaction elements and timetable with regard to the public-to-private and financing transaction between AMT and uniQure BV
Apr 26, 2012
Amsterdam Molecular Therapeutics completes advance distribution of uniQure depositary receipts to AMT shareholders
Apr 6, 2012
Amsterdam Molecular Therapeutics announces completion of disposal of its operations to uniQure B.V. and its dissolution becoming effective
Mar 8, 2012
uniQure Q&A
Feb 20, 2012
Invitation to informational meeting – February 23, 2012
Feb 17, 2012
Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV
Archived News Releases
2012
2011
Archived AMT Press Releases
Click here to view the current and archived press releases from AMT